Psoriasis

Many patients struggle with therapeutic control, adverse effects, and costs of psoriasis treatments, prompting a renewed focus on alternative treatments like phototherapy.

April Armstrong, MD, MPH, chief of dermatology, UCLA, discusses clinical trial findings from the phase 2b study on zasocitinib.

Findings from a new study reveal significant racial differences in skin biopsy frequency for psoriasis diagnosis, indicating potential diagnostic challenges, particularly for Black patients.

A phase 2b clinical trial demonstrates the potential of zasocitinib in achieving biologic-level efficacy with minimal adverse effects.

Amgen announces new FDA-approved oral treatment option for children and adolescents with moderate to severe plaque psoriasis.

This new study confirms the noninferiority of extended dosing intervals for psoriasis control in super responders.

A recent study found psoriasis content deemed “unreliable” still obtained 850,000 likes.

Inflammatory markers can indicate treatment efficacy and predict super-responder status in patients with psoriasis treated with biologics, according to one study.

Biologic therapies may be less effective in patients with certain clinical characteristics, a meta-analysis found.

Patients with moderate-to-severe plaque psoriasis experienced early and sustained improvements through 108 weeks of treatment.

Patients with a later onset of psoriasis (PsO) may benefit from earlier screening for psoriatic arthritis (PsA), according to one study.

A bidirectional risk between psoriasis and asthma has been identified, according to one study.

Researchers have identified a link between psoriasis and the autoimmune diseases hypothyroidism and alopecia areata.

Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center, discusses how diversity in clinical trials are helping bridge the racial health equity gap in psoriasis care.

Researchers evaluated the impact of different treatment modalities in the prevention of psoriatic arthritis (PsA).

Patients with moderate to severe psoriasis may benefit from weekend cyclosporine treatment (WCT) as a maintenance therapy, according to one study.

Psychological well-being should be considered in the management of psoriasis, research indicates.

Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center, discusses ways to overcome barriers in clinical trials for diverse patients with psoriasis.

Botulinum toxin A (BoNT-A) exhibited promising results for nail psoriasis for up to 6 months with a single injection.

Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center, discusses how to accurately represent findings from diverse populations and translate them into clinical practice.

Efficacy results support long-term use of risankizumab in patients with active psoriatic arthritis across multiple patient and psoriatic disease characteristics.

Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.

Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, addresses challenges in identifying patients with generalized pustular psoriasis (GPP) and how artificial intelligence (AI) can help alleviate these concerns.

Patients with moderate to severe psoriasis and a history of cancer have improved symptoms and a favorable safety profile with guselkumab treatment, according to a new study.

Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, discusses ways that AI is being integrated into personalized medicine for patients with generalized pustular psoriasis (GPP).